Project Grant R01AI200600

The National Institute of Allergy and Infectious Diseases awarded Trustees of Indiana University (doing business as Indiana University) $617,374 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define nuclear pore complex subsets and import pathways that regulate HIV-1 integration and gene expression.

The research will characterize how HIV-1 exploits nuclear pore complex remodeling and host factors to gain access to the nucleus in non-dividing cells, and how distinct nuclear import routes influence productive versus latent infection outcomes in CD4 T cells and macrophages. The project will employ chemically induced nuclear pore complex blockades, degron-mediated acute depletion of nucleoporins, CRISPR-based editing, and chromatin profiling approaches including ChIP-seq and integration site mapping to define the molecular composition and remodeling of nuclear pore complex subsets engaged by HIV-1, determine how alternate import pathways redirect integration into repressive chromatin, and characterize how nuclear entry pathways dictate the epigenetic landscape. The work aims to identify therapeutic targets for blocking infection or selectively re-directing latent infection outcomes.

Performance occurs in Bloomington, Indiana. The award period runs through July 31, 2031.